Heart failure & cardiomyopathies
Safety of Sodium-Glucose Cotransporter 2 Inhibitors Drugs Among Heart Failure Patients: A Systematic Review and Meta-Analysis
Authors' conclusion
Our meta-analysis demonstrated that using SGLT2is in HF patients was correlated with reduced mortality and SAEs, with a more prominent effect in HF with reduced ejection fraction patients and those taking dapagliflozin.
Study context
- Population
- Patients with heart failure (HF)18 studies
- Participants
- 12,925 vs 12,747
- Comparison
- SGLT2i vs placebo
- SGLT2in = 12,925
- Placebon = 12,747reference
- Outcome
- Safety outcomes of SGLT2i
Methodological detailscommon-effect meta-analysis
- Common-effect meta-analysis
Pooled result
As reported in the abstract
All-cause mortality and serious adverse events
SGLT2i vs PlaceboRelative risk (95% CI)P value
All-cause mortality; I2 = 0%
0.91(0.85–0.97)
P = 0.005SAEs; I2 = 43%
0.92(0.90–0.95)
P < 0.001Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Volume depletion and genitourinary infectionsSGLT2i vs Placebo · volume depletion; I2 = 0% | 1.17 (1.06–1.28) | P = 0.001 | |
| Volume depletion and genitourinary infectionsSGLT2i vs Placebo · genitourinary infections; I2 = 17% | 1.27 (1.13–1.43) | P < 0.001 | |
| 0.512Relative risk (log scale) |
Original publication
Safety of Sodium-Glucose Cotransporter 2 Inhibitors Drugs Among Heart Failure Patients: A Systematic Review and Meta-Analysis. ESC Heart Fail. Published 20 December 2023. doi:10.
Summarised from the published abstract; every number is checked against it